Veränderungen der Knochendichte bei der Behandlung des mCSPC – Ergebnisse aus der PEACE-1-Studie
Nach relativ kurzer Zeit zeigte sich bei Standardbehandlung mit und ohne Abirateron ein früher Knochendichteabbau.
„PEACE-1 Shows That Bone Loss Is a Concern With Treatment of mCSPC, Underscoring the Importance of Routine Bone Mineral Density Assessment“
https://dailynews.ascopubs.org/do/10.1200/ADN.22.200854/full/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=ASCO_Daily_News_TrendMD_0
„- Results from PEACE-1 showed early, rapid, clinically meaningful bone loss following standard treatment with or without abiraterone in patients with metastatic castration-sensitive prostate cancer.
- By 2 years posttreatment, bone loss changes were similar for the groups who received standard treatment alone or standard treatment in combination with abiraterone.“
und
„A prospective evaluation of bone mineral density (BMD) in men with metastatic castration-sensitive prostate cancer (mCSPC) who participated in the PEACE-1 trial confirms that bone loss occurs early following standard treatment with androgen deprivation therapy (ADT) and docetaxel with or without the addition of abiraterone and prednisone (AAP; Abstract 19).“
“The findings remind us that it is crucial to take into account bone loss by treating risk factors of osteoporosis and assessing BMD. Dr. Guilhem Roubaud"
----------------------------------------------------------
Zum Abstract mit Ergebnistabelle:
„Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.“
Franz
Nach relativ kurzer Zeit zeigte sich bei Standardbehandlung mit und ohne Abirateron ein früher Knochendichteabbau.
„PEACE-1 Shows That Bone Loss Is a Concern With Treatment of mCSPC, Underscoring the Importance of Routine Bone Mineral Density Assessment“
https://dailynews.ascopubs.org/do/10.1200/ADN.22.200854/full/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=ASCO_Daily_News_TrendMD_0
„- Results from PEACE-1 showed early, rapid, clinically meaningful bone loss following standard treatment with or without abiraterone in patients with metastatic castration-sensitive prostate cancer.
- By 2 years posttreatment, bone loss changes were similar for the groups who received standard treatment alone or standard treatment in combination with abiraterone.“
und
„A prospective evaluation of bone mineral density (BMD) in men with metastatic castration-sensitive prostate cancer (mCSPC) who participated in the PEACE-1 trial confirms that bone loss occurs early following standard treatment with androgen deprivation therapy (ADT) and docetaxel with or without the addition of abiraterone and prednisone (AAP; Abstract 19).“
“The findings remind us that it is crucial to take into account bone loss by treating risk factors of osteoporosis and assessing BMD. Dr. Guilhem Roubaud"
----------------------------------------------------------
Zum Abstract mit Ergebnistabelle:
„Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.“
Franz
Kommentar